Nanoscope strengthens_thumbnail
September 4, 2025

Nanoscope Secures Major Global Wins for MCO-010 with EMA and FDA Designations

The race to restore sight for patients living with retinal degeneration just gained serious momentum.  Nanoscope Therapeutics (Texas, United States)…

first patients treated in jCyte_Thumbnail
August 20, 2025

First Patients Dosed in jCyte’s Phase II JC02-88 Trial for Retinitis Pigmentosa

jCyte turns up the dose, chasing broader answers for a disease with few options.  A higher dose, a broader target…

popular posts
ENCELTO implant releasing neurotrophic factor
August 15, 2025

U.S. Patient Receives World’s First ENCELTO Gene Therapy for MacTel

latest posts
Nanoscope strengthens_thumbnail
September 4, 2025

Nanoscope Secures Major Global Wins for MCO-010 with EMA and FDA Designations

first patients treated in jCyte_Thumbnail
August 20, 2025

First Patients Dosed in jCyte’s Phase II JC02-88 Trial for Retinitis Pigmentosa

ENCELTO implant releasing neurotrophic factor
August 15, 2025

U.S. Patient Receives World’s First ENCELTO Gene Therapy for MacTel

AI assistance improves AM diagnosis_thumbnail
July 18, 2025

AI improves AMD diagnosis accuracy and speed. But can we trust it?

Artboard_1
July 16, 2025

AI System Eye2Gene Shows Promise in Rapid Genetic Diagnosis of Inherited Retinal Diseases

Nanoscope updates thumbnail
July 15, 2025

Nanoscope Kickstarts BLA Submission for Restorative RP Therapy, Adds to Advisory Board

Perfuse_phase_II_glaucoma_thumbnail
June 27, 2025

Perfuse Therapeutics Shares Promising Phase IIa Results in Glaucoma and Diabetic Retinopathy

Ocugen_thumbnail
June 17, 2025

FDA Clears Ocugen’s Phase II/III Trial for Stargardt Disease Gene Therapy

Discover our fascinating content at issuu

explore